Pramipexole-induced limb dystonia and its associated complex regional pain syndrome in idiopathic Parkinson's disease

Park, Donghwi

doi:10.1097/md.0000000000007530

Cited by 14 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRPS is a chronic pain condition of modest prevalence in the overall population and relatively high incidence after injuries and surgeries to the extremities 3 21–23. Immobilization due to the fracture of an extremity is a common set of circumstances leading to CRPS 23.…”

Section: Discussionmentioning

confidence: 99%

Sphingosine 1-phosphate receptor modulation attenuate mechanical allodynia in mouse model of chronic complex regional pain syndrome by suppressing pathogenic astrocyte activation

Lee

Kim

Cho

et al. 2020

Reg Anesth Pain Med

Self Cite

View full text Add to dashboard Cite

Background and objectivesFTY720 ((2-amino-2-)2-[4-octylphenyl]ethyl)-1,3-propanediol) is an Food and Drug Administration (FDA)-approved immunomodulatory drug for treating multiple sclerosis. It inhibits lymphocyte egression from lymphoid tissues by downregulating sphingosine-1 phosphate receptor (S1PR). To date, there has been no study on the effects of FTY720 on the chronic stage of the complex regional pain syndrome (CRPS) rodent model, despite its antiallodynic effect in previous studies. Thus, the aim of this study is to investigate the effect of FTY720 in a chronic stage of the CRPS mouse model.MethodThe authors used a mouse model of CRPS, involving tibia fracture/cast immobilization, to test the efficacy of intrathecal FTY720 (2.5 or 25 ng daily; 6 days) or vehicle during the chronic (7 weeks after fracture) stage of CRPS.ResultsIntrathecal recombinant FTY720 administration was antiallodynic in the chronic stage of the CRPS mouse model, and such an effect of FTY720 developed by modulating astrocyte activation in the spinal cord. Additionally, according to the in vitro data, the FTY720 treatment inhibited S1P-induced increase in the nitric oxide production and suppression of the NF-κB pathway, by inhibiting the phosphorylation of NF-κB/p65 in astrocytes without toxic effect on astrocytes.ConclusionCollectively, these results demonstrate that intrathecally administered FTY720 attenuates mechanical allodynia in the chronic stage of the CRPS mouse model.

show abstract

Section: Discussionmentioning

confidence: 99%

Sphingosine 1-phosphate receptor modulation attenuate mechanical allodynia in mouse model of chronic complex regional pain syndrome by suppressing pathogenic astrocyte activation

Lee

Kim

Cho

et al. 2020

Reg Anesth Pain Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…This was probably due to two reasons: 1) an insufficient amount or duration of intrathecal IL-10 administration to prevent the transition to the chronic stage despite the effective decrease of neuro-inflammation in the acute stage of CRPS; 2) the possibility of central sensitization by mechanisms other than neuro-inflammation by spinal glial activation, such as supra-spinal structures. Considering that some clinical studies have shown evidence that other than the spinal cord, the prefrontal cortex, 34 thalamus, 8 and the basal ganglia, 35 play an important role in the development of central sensitization of CRPS, further studies will be needed to elucidate the underlying mechanism of central sensitization other than neuro-inflammation in the CRPS.…”

Section: Discussionmentioning

confidence: 99%

Anti-allodynic effect of interleukin 10 in a mouse model of complex regional pain syndrome through reduction of NK1 receptor expression of microglia in the spinal cord

Kim¹,

Park²,

Park³

2018

JPR

Self Cite

View full text Add to dashboard Cite

BackgroundTo date, there has been no study on the effects of interleukin-10 (IL-10) on complex regional pain syndrome (CRPS) rodent models, despite the anti-allodynic effect of IL-10 in previous studies. Thus, the aim of this study was to investigate the effect of IL-10 in a CRPS mouse model and find whether early inhibition of neuro-inflammation by IL-10 administration, which is considered to be one of the important mechanisms in the generation of central sensitization, could prevent the transition from the acute stage to the chronic stage of CRPS.MethodA mouse model of CRPS (n=6/group) involving tibia fracture/cast immobilization to test the efficacy of intrathecal IL-10 (0.3 μg/5 μL−1 day−1 for 7 days) or vehicle during the acute (3 weeks after fracture) stage of CRPS.ResultsIntrathecal recombinant IL-10 (rIL-10) administration was anti-allodynic in the acute stage of the CRPS mouse model, and these anti-allodynic effects of IL-10 developed by modulating microglial activation and decreasing NK1 receptor expression in the spinal cord. However, intrathecal rIL-10 administration in the acute stage of the CRPS mouse model cannot prevent the transition to the chronic stage of CRPS in the acute stage of CRPS.ConclusionCollectively, these results demonstrate that intrathecally administered rIL-10 attenuates mechanical allodynia in the CRPS mouse model. However, this effect of IL-10 on allodynia in the acute stage of CRPS was not sufficient to prevent the transition to the chronic stage of CRPS. In the future, further studies about the mechanisms of central sensitization in CRPS will be necessary.

show abstract

“…Journal of Pain Research 2020:13 contributes a little more to the acute stage of CRPS than to the chronic stage. [23][24][25][26][27][28] The disease durations were 2.4 ± 0.9 and 1.6 ± 0.7 years in studies conducted in 2017 and 2010, respectively. 15,16 Therefore, the greater effect of IVIG in the study by Goebel et al in 2010 16 compared to 2017 15 may be explained by the enrollment of patients in a relatively early phase of CRPS.…”

Section: Dovepressmentioning

confidence: 96%

<p>Effectiveness of Intravenous Immunoglobulin for Management of Neuropathic Pain: A Narrative Review</p>

Lee¹,

Park²

2020

JPR

Self Cite

View full text Add to dashboard Cite

Administrations of intravenous immunoglobulin (IVIG), an immune-modulating blood-derived product, may be beneficial for managing neuropathic pain. Here, we review previous studies to investigate the effectiveness of IVIG in managing neuropathic pain due to various neurological disorders. The electronic databases PubMed, Scopus, Embase, and the Cochrane Library were searched for studies published up to February 2020. Two reviewers independently assessed the studies using strict inclusion criteria. Ten studies were included and qualitatively analyzed. The review included patients with pain due to complex regional pain syndrome (CRPS), diabetic polyneuropathy, and others, such as postherpetic neuralgia and trigeminal neuralgia. We found that IVIG may be one of the beneficial options for managing neuropathic pain from various neurological disorders. In the four articles reviewed, no major adverse effects were reported, and the trend was toward a positive pain-reducing effect in eight articles. However, to confirm the benefits of IVIG on reducing neuropathic pain, more high-quality studies are required.

show abstract

Pramipexole-induced limb dystonia and its associated complex regional pain syndrome in idiopathic Parkinson's disease

Cited by 14 publications

References 16 publications

Sphingosine 1-phosphate receptor modulation attenuate mechanical allodynia in mouse model of chronic complex regional pain syndrome by suppressing pathogenic astrocyte activation

Sphingosine 1-phosphate receptor modulation attenuate mechanical allodynia in mouse model of chronic complex regional pain syndrome by suppressing pathogenic astrocyte activation

Anti-allodynic effect of interleukin 10 in a mouse model of complex regional pain syndrome through reduction of NK1 receptor expression of microglia in the spinal cord

<p>Effectiveness of Intravenous Immunoglobulin for Management of Neuropathic Pain: A Narrative Review</p>

Contact Info

Product

Resources

About